The landscape of new drugs in lymphoma

Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Franck Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Marie Vose

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.

Original languageEnglish (US)
Pages (from-to)335-346
Number of pages12
JournalNature Reviews Clinical Oncology
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Lymphoma
Pharmaceutical Preparations
Investigational Drugs
Expert Testimony
Patient Selection
Cost-Benefit Analysis
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., ... Vose, J. M. (2017). The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology, 14(6), 335-346. https://doi.org/10.1038/nrclinonc.2016.205

The landscape of new drugs in lymphoma. / Younes, Anas; Ansell, Stephen; Fowler, Nathan; Wilson, Wyndham; de Vos, Sven; Seymour, John; Advani, Ranjana; Forero, Andres; Morschhauser, Franck; Kersten, Marie Jose; Tobinai, Kensei; Zinzani, Pier Luigi; Zucca, Emanuele; Abramson, Jeremy; Vose, Julie Marie.

In: Nature Reviews Clinical Oncology, Vol. 14, No. 6, 01.06.2017, p. 335-346.

Research output: Contribution to journalReview article

Younes, A, Ansell, S, Fowler, N, Wilson, W, de Vos, S, Seymour, J, Advani, R, Forero, A, Morschhauser, F, Kersten, MJ, Tobinai, K, Zinzani, PL, Zucca, E, Abramson, J & Vose, JM 2017, 'The landscape of new drugs in lymphoma', Nature Reviews Clinical Oncology, vol. 14, no. 6, pp. 335-346. https://doi.org/10.1038/nrclinonc.2016.205
Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J et al. The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology. 2017 Jun 1;14(6):335-346. https://doi.org/10.1038/nrclinonc.2016.205
Younes, Anas ; Ansell, Stephen ; Fowler, Nathan ; Wilson, Wyndham ; de Vos, Sven ; Seymour, John ; Advani, Ranjana ; Forero, Andres ; Morschhauser, Franck ; Kersten, Marie Jose ; Tobinai, Kensei ; Zinzani, Pier Luigi ; Zucca, Emanuele ; Abramson, Jeremy ; Vose, Julie Marie. / The landscape of new drugs in lymphoma. In: Nature Reviews Clinical Oncology. 2017 ; Vol. 14, No. 6. pp. 335-346.
@article{70dcb45b07c94c5791830db7dacf5b94,
title = "The landscape of new drugs in lymphoma",
abstract = "The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.",
author = "Anas Younes and Stephen Ansell and Nathan Fowler and Wyndham Wilson and {de Vos}, Sven and John Seymour and Ranjana Advani and Andres Forero and Franck Morschhauser and Kersten, {Marie Jose} and Kensei Tobinai and Zinzani, {Pier Luigi} and Emanuele Zucca and Jeremy Abramson and Vose, {Julie Marie}",
year = "2017",
month = "6",
day = "1",
doi = "10.1038/nrclinonc.2016.205",
language = "English (US)",
volume = "14",
pages = "335--346",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The landscape of new drugs in lymphoma

AU - Younes, Anas

AU - Ansell, Stephen

AU - Fowler, Nathan

AU - Wilson, Wyndham

AU - de Vos, Sven

AU - Seymour, John

AU - Advani, Ranjana

AU - Forero, Andres

AU - Morschhauser, Franck

AU - Kersten, Marie Jose

AU - Tobinai, Kensei

AU - Zinzani, Pier Luigi

AU - Zucca, Emanuele

AU - Abramson, Jeremy

AU - Vose, Julie Marie

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.

AB - The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85007452319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007452319&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2016.205

DO - 10.1038/nrclinonc.2016.205

M3 - Review article

C2 - 28031560

AN - SCOPUS:85007452319

VL - 14

SP - 335

EP - 346

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 6

ER -